Accordingly, V1bR antagonists did not show statistically significant efficacy in clinical trials for major depressive disorder and generalized anxiety disorder (Griebel et al, 2012; Chaki, 2021; Kamiya et al, 2020). Here, AVPR1B is linked to generalized anxiety disorder.